Jasper Therapeutics (JSPR) EBT (2020 - 2025)

Jasper Therapeutics has reported EBT for 6 years, with the latest figure at -$15.5 million in Q4 2025.

• On a quarterly basis, EBT rose 36.33% year-over-year to -$15.5 million in Q4 2025; TTM through Dec 2025 was -$82.1 million, a 15.3% decrease from a year earlier, with the FY2025 full-year figure at -$82.1 million, down 15.4% from the prior year.
• EBT was -$15.5 million for Q4 2025 at Jasper Therapeutics, up from -$18.8 million in the prior quarter.
• The five-year high for EBT was $5.5 million in Q1 2021, with the low at -$26.6 million in Q2 2025.
• Average EBT over 5 years is -$14.4 million, with a median of -$14.1 million recorded in 2024.
• The largest YoY upside for EBT was 269.82% in 2021 against a maximum downside of 4713.14% in 2021.
• Over 5 years, EBT stood at -$12.1 million in 2021, then retreated by 10.9% to -$13.4 million in 2022, then fell by 23.08% to -$16.5 million in 2023, then tumbled by 47.64% to -$24.3 million in 2024, then jumped by 36.33% to -$15.5 million in 2025.
• The last three EBT figures came in at -$15.5 million (Q4 2025), -$18.8 million (Q3 2025), and -$26.6 million (Q2 2025), per Business Quant data.